SCHEDULE: Goldman Sachs Reports 2.0% Stake in Fate Therapeutics

Goldman Sachs Group reports beneficial ownership of 2.0% of Fate Therapeutics' common stock as of June 30, 2025.

Summary

• The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly filed a Schedule 13G amendment for Fate Therapeutics, Inc.
• As of June 30, 2025, Goldman Sachs Group beneficially owns 2,274,020.09 shares of Fate Therapeutics, Inc., representing 2.0% of the company's common stock.
• Goldman Sachs & Co. LLC also reports beneficial ownership of 2,274,020.09 shares, representing 2.0% of the common stock.
• The filing indicates shared voting power over 2,273,623.09 shares and shared dispositive power over 2,274,020.09 shares for both reporting entities.

Sentiment

Score: 5

Explanation: The filing is a standard ownership disclosure, with neutral sentiment.

Positives

• Goldman Sachs' continued holding in Fate Therapeutics may indicate confidence in the company's prospects.

Future Outlook

NA

Industry Context

This filing is a routine disclosure related to institutional ownership and doesn't necessarily reflect a strategic shift in the biotechnology industry.

Stakeholder Impact

• Shareholders: Awareness of institutional ownership percentages.
• Company: Compliance with SEC regulations regarding ownership disclosure.

Key Dates

Recommendation

The filing indicates a consistent ownership stake by a major financial institution, suggesting a neutral outlook. No specific buy or sell signals are apparent.

Keywords

Schedule 13G, Fate Therapeutics, Goldman Sachs, Beneficial Ownership, Common Stock, SEC Filing